First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma

Journal of Clinical Neuroscience

Volumn 22, Issue 12, 2015, Pages 1889-1894

  Whittle, James R ^a   Lickliter, Jason D ^b   Gan, Hui K ^c   Scott, Andrew M ^c   Simes, John ^d   Solomon, Benjamin J ^e   MacDiarmid, Jennifer A ^f   Brahmbhatt, Himanshu ^f   Rosenthal, Mark A ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b Melbourne Children's Sleep Centre   (Australia)

^c AUSTIN HOSPITAL   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f Engeneic Ltd   (Australia)

Author keywords

Doxorubicin; Epidermal growth factor receptor; First in human; Glioblastoma; Phase I trial

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PANITUMUMAB; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CHILL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; GLIOBLASTOMA; HEADACHE; HUMAN; HUMAN TISSUE; HYPOPHOSPHATEMIA; HYPOTENSION; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NANOPHARMACEUTICS; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RIGOR; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; AUSTRALIA; BRAIN NEOPLASMS; CLINICAL TRIAL; IMMUNOHISTOCHEMISTRY; MOLECULARLY TARGETED THERAPY; NANOTECHNOLOGY; PROCEDURES; TUMOR RECURRENCE;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AUSTRALIA; BRAIN NEOPLASMS; DOXORUBICIN; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MAXIMUM TOLERATED DOSE; MOLECULAR TARGETED THERAPY; NANOTECHNOLOGY; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84948711443     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2015.06.005     Document Type: Article

References (30)

1. Q.T. Ostrom, H. Gittleman, P. Farah, and et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010 Neuro Oncol 15 2013 ii1 ii56
2. E.T. Wong, K.R. Hess, M.J. Gleason, and et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials J Clin Oncol 17 1999 2572 2578
3. H.S. Friedman, M.D. Prados, P.Y. Wen, and et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 2009 4733 4740
4. J.A. MacDiarmid, and H. Brahmbhatt Minicells: versatile vectors for targeted drug or si/shRNA cancer therapy Curr Opin Biotechnol 22 2011 909 916
5. I.K. Mellinghoff, M.Y. Wang, I. Vivanco, and et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors N Eng J Med 353 2005 2012 2024
6. J. Mendelsohn, and J. Baselga Epidermal growth factor receptor targeting in cancer Semin Oncol 33 2006 369 385
7. M.K. Nicholas, R.V. Lukas, N.F. Jafri, and et al. Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas Clin Cancer Res 12 2006 7261 7270
8. J.J. Raizer, L.E. Abrey, A.B. Lassman, and et al. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy Neuro Oncol 12 2010 95 103
9. J.N. Rich, D.A. Reardon, T. Peery, and et al. Phase II trial of gefitinib in recurrent glioblastoma J Clin Oncol 22 2004 133 142
10. S. Merry, S.B. Kaye, and R.I. Freshney Cross-resistance to cytotoxic drugs in human glioma cell lines in culture Br J Cancer 50 1984 831 835
11. A.C. Stan, S. Casares, D. Radu, and et al. Doxorubicin-induced cell death in highly invasive human gliomas Anticancer Res 19 1999 941 950
12. J.E. Wolff, T. Trilling, G. Molenkamp, and et al. Chemosensitivity of glioma cells in vitro: a meta analysis J Cancer Res Clin Oncol 125 1999 481 486
13. M.S. Lesniak, U. Upadhyay, R. Goodwin, and et al. Local delivery of doxorubicin for the treatment of malignant brain tumors in rats Anticancer Res 25 2005 3825 3831
14. K.A. Walter, R.J. Tamargo, A. Olivi, and et al. Intratumoral chemotherapy Neurosurgery 37 1995 1128 1145
15. S.L. Chua, M.A. Rosenthal, S.S. Wong, and et al. Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme Neuro Oncol 6 2004 38 43
16. S. Ananda, A.K. Nowak, L. Cher, and et al. Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy J Clin Neurosci 18 2011 1444 1448
17. M. Glas, H. Koch, B. Hirschmann, and et al. Pegylated liposomal doxorubicin in recurrent malignant glioma: analysis of a case series Oncology 72 2007 302 307
18. P. Hau, K. Fabel, U. Baumgart, and et al. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma Cancer 100 2004 1199 1207
19. K. Fabel, J. Dietrich, P. Hau, and et al. Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin Cancer 92 2001 1936 1942
20. K. Clarke, R.L. Basser, C. Underhill, and et al. KRN8602 (MX2-hydrochloride): an active new agent for the treatment of recurrent high-grade glioma J Clin Oncol 17 1999 2579 2584
21. B. Solomon, J. Desai, A. Scott, and et al. First-in-man, multicenter, phase I trial evaluating the safety of first-in-class therapeutic, EGFR-targeted, paclitaxel-packaged minicells Eur J Cancer 48 2012 179
22. P.Y. Wen, D.R. Macdonald, D.A. Reardon, and et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group J Clin Oncol 28 2010 1963 1972
23. R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1989 1 10
24. F. Nava, I. Tramacere, A. Fittipaldo, and et al. Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010 Neuro Oncol 16 2014 719 727
25. P.Y. Wen, and S. Kesari Malignant gliomas in adults New Engl J Med 359 2008 492 507
26. J.N. Rich, B.K. Rasheed, and H. Yan EGFR mutations and sensitivity to gefitinib New Engl J Med 351 2004 1260 1261 [author reply 1260-1]
27. J.A. MacDiarmid, N.B. Mugridge, J.C. Weiss, and et al. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics Cancer Cell 11 2007 431 445
28. I. Vivanco, H.I. Robins, D. Rohle, and et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors Cancer Discov 2 2012 458 471
29. A.S. Gajadhar, E. Bogdanovic, D.M. Munoz, and et al. In situ analysis of mutant EGFRs prevalent in glioblastoma multiforme reveals aberrant dimerization, activation, and differential response to anti-EGFR targeted therapy Mol Cancer Res 10 2012 428 440
30. W.M. Pardridge Drug transport across the blood-brain barrier J Cereb Blood Flow Metab 32 2012 1959 1972